Business Wire

Completion of Clinical Trial - a Significant Achievement for Medicortex Finland

Jaa

Medicortex Finland Oy ( http://www.medicortex.fi ), a biotechnology company developing a diagnostic kit for brain injury detection based on a medical breakthrough biomarker, completed collection of samples in its second large clinical study. The trial recruited patients who came to the hospital due to a head injury or orthopedic injury and compared them to healthy volunteers.

"Collecting the human samples in this large clinical trial is a significant achievement for Medicortex, and represents an important step forward in the development of the ProbTBITM, a diagnostic kit for head injury" said Dr. Adrian Harel, Chief Executive Officer of Medicortex Finland. "Brain injury is a devastating condition leading to medical complications if not diagnosed. We have the opportunity to develop a portable non-invasive kit for quick detection of mild traumatic brain injury and concussion, and to help patients and families that so desperately need it “

In the clinical trial Medicortex collected body fluid samples from total of 68 subjects, consisting of patients with head injury, patients with orthopedic injury, and healthy volunteers. Two main Finnish hospitals, Turku University hospital and Satakunta Central Hospital in Pori, served as study sites recruiting the patients and collecting the samples. The next step is analyzing the samples for the presence of the novel biomarker and to demonstrate statistical difference between the patients and healthy control subjects. “The biomarker we are targeting has never before been used for mild brain injury detection. The fact that we can readily find it in easily accessible body fluids such as urine and saliva enable us to develop a user-friendly diagnostic kit for concussion and mild TBI detection”, says Dr. Harel.

Dr. Marten Kvist, Medical Director of Medicortex, says "We are excited of the clinical step which will confirm the diagnostic feasibility of the unique biomarker, it will be further developed into a diagnostic aid for first responders and paramedics, it will help prioritize evacuation and reframe from administration of contraindicated medications."

Medicortex is working towards the validation of a Traumatic Brain Injury (TBI) biomarker and incorporating it into a quick and reliable diagnostic kit (ProbTBITM) that can be easily used by the first responders and healthcare professionals.

Medicortex is currently raising money for the next step of clinical development and kit development. Everyone can help to develop the new diagnostic kit by investing.

About Medicortex

Medicortex Finland Oy (http://www.medicortex.fi) is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is to develop biomarker diagnostics that evaluate the extent and severity of TBI. Once the company completes the biomarker development its next goal will be to develop an innovative drug to halt the progression of brain injury.

Key words: NFL, ice-hockey, rugby, brain injury, head injury, concussion, diagnostics, TBI, sport, professional athletes, boxing, early detection, military, army, navy, soldier, combat, veteran, trauma, PTSD, clinical trial

Forward-Looking Statements

This press release contains statements that are "forward-looking statements" that are based upon management's current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated herein.

Contact information

Dr. Adrian Harel - CEO
Medicortex Finland Oy
Tel. +358 (0) 400 488 817
Fax. +358 (0) 2 251 0100
adrian.harel@medicortex.fi
http://www.medicortex.fi

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Earth Networks and RIMES Announce Technical Collaboration to Benefit Member Government Weather Services27.3.2019 02:00:00 EETTiedote

Earth Networks, a global provider of weather intelligence, announced today it has partnered with the Regional Integrated Multi-Hazard Early Warning System for Africa and Asia (RIMES). The partnership will enable a multi-year collaboration program to enhance RIMES’ member state National Hydro-Meteorological Services (NMHS) capacity for early warning of severe weather. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Together, the two organizations are working to improve access to reliable weather information and early warning capabilities in Africa and Asia. By contributing on-the-ground insights from its weather and lightning networks, Earth Networks is providing critical hyperlocal data to RIMES to help regional NMHS close weather observation gaps in real-time and support more accurate forecasting. These technology enhancements will result in quicker warnings to the public before and during severe weather events. Earth Networks has years of experience

Huawei Rewrites the Rules of Photography with Groundbreaking HUAWEI P30 Series26.3.2019 19:04:00 EETTiedote

During an exclusive launch event today at the Paris Convention Center, Huawei Consumer Business Group (BG) unveiled the HUAWEI P30 and HUAWEI P30 Pro. The HUAWEI P30 Series builds on the HUAWEI P Series DNA in design and photography and is the company’s most advanced series of smartphone cameras. These devices feature the innovative HUAWEI SuperSpectrum Sensor, an optical SuperZoom Lens, a new HUAWEI Time of Flight (ToF) Camera, and enhanced optical and AI image stabilization technology. With these revolutionary technologies, the HUAWEI P30 and HUAWEI P30 Pro capture incredible photos and videos in every scenario. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005752/en/ HUAWEI P30 Series (Photo: Business Wire) Richard Yu, CEO of Huawei Consumer BG, said, “the HUAWEI P30 Series is a fundamental breakthrough after decades of digital camera technology development; it will rewrite the rules and reshape everyone’s percepti

Takeda Presents New Data at the Endocrine Society’s 2019 Annual Meeting about the Patient Burden and Long-Term Impact of Chronic Hypoparathyroidism26.3.2019 18:01:00 EETTiedote

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) this week shared new data revealing the burden of chronic hypoparathyroidism on patients and caregivers, as well as potential long-term risks of renal and cardiovascular complications that patients treated with conventional therapy may experience. Six-year results from the open-label long-term safety and efficacy RACE study were also announced. Data was presented at the Endocrine Society’s 2019 Annual Meeting (ENDO) from 23–26 March in New Orleans, Louisiana, USA. “Results from the Burden of Illness Global Survey in 13 countries reveal the extent of the impact hypoparathyroidism has on patients and their caregivers throughout their daily lives,” said John Bilezikian M.D., Professor of Medicine at the Columbia University Irving Medical Center, New York, NY, USA. “This offers important insights and enables us to take a more holistic approach in the management of these patients due to a greater understanding of the poten

LEO Pharma Standardizes on Veeva Development Cloud to Speed Drug Development26.3.2019 17:58:00 EETTiedote

Veeva Systems (NYSE:VEEV) today announced that LEO Pharma, a global leader in medical dermatology, selected Veeva Development Cloud applications to help drive end-to-end business processes across product development. The company will utilize the Vault Clinical, Vault RIM, and Vault Quality suites to unify drug development on a single cloud platform. With Veeva Development Cloud, LEO Pharma can bring together applications for clinical, regulatory, and quality for even greater efficiency and compliance throughout the product development lifecycle. “LEO Pharma R&D has embarked on an ambitious strategy for 2025, which will pave the way for our ambitions to continuously pioneer dermatology. This requires that we are able to drive science globally, whilst at the same time securing timely delivery on our pipeline,” said Kim Kjøller, executive vice president of global research and development at LEO Pharma. “Veeva Development Cloud gives us a unified platform that can enable us to maximize eff

Keio Plaza Hotel Tokyo Hosts Japanese Sword Culture, Armor Exhibition – “Japan’s Soul and Beauty of Swords and Armor by Legendary Artisans”26.3.2019 17:05:00 EETTiedote

Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will host a special exhibition entitled “Japan’s Soul and Beauty of Swords and Armor by Legendary Artisans” displaying beautiful Japanese swords and armor from April 25 (Thursday) to June 27 (Thursday), 2019 in the 3rd floor lobby of our Hotel. This exhibition is part of our series of cultural programs designed to introduce various aspects of Japanese culture to our guests visiting the Hotel from over 100 different countries around the world. Various precious and old swords and armor made during the Heian Period (794-1185) and other periods of Japanese history will be displayed, along with “tsuba” (Sword handle guards separating the handle from the blade) and other ornate sword fittings. On May 14, two masters of sword-drawing from Ryushin Shouchi School will give a live performance in the Main lobby from 5:00 p.m. This press release features multimedia. View the full release

Andersen Global Enters Qatar26.3.2019 16:30:00 EETTiedote

Andersen Global today announced a collaborating agreement in Qatar with Al-Khalifa Law, a leading Doha-based law firm. The collaboration is Andersen Global’s first in Qatar and is part of the organization’s continued growth in the Middle East. Al-Khalifa Law was founded 20 years ago and established itself as a premier firm in the region. The team at Al-Khalifa Law has diversified, deep experience providing services in a wide variety of business sectors, such as commercial contracts, taxation, employment, real estate and retail, intellectual property, dispute resolution and litigation and arbitration. “A collaboration with Andersen Global, which brings with it a culture of stewardship, transparency, and providing best-in-class services, was an obvious decision for us,” said Hamzeh Abdelhady, Office Managing Director of Al-Khalifa Law. “We will be able to continue providing quality services in the market and bring a premier, seamless association of experts throughout the world directly t

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme